Table 2.

Cumulative incidence of bisphosphonate associated osteonecrosis of the jaw in the oncology patient population.

StudyDesignBasal ConditionNo. of PatientsCumulative Incidence, %Time of Followup, mo
Bamias39*Retrospective cohort with a prospective componentBone metastasis of different primary tumors including multiple myeloma252**012
324
736
1148
Dimopoulous68*Retrospective cohort with a prospective componentMultiple myeloma202**112
324
636
1348
Tosi69Retrospective cohort studyMultiple myeloma2596.624
Durie66SurveyMultiple myeloma (75%) and breast cancer (25%)1203**736
Cafro70Retrospective review of casesMultiple myeloma10412.036
Pozzi71Retrospective multicenter review of casesMultiple myeloma18421.936

  • ↵* There is substantial duplication of cases between these 2 studies.

  • ↵** Incidence was estimated with survival analysis.